CAR-T Therapies: Access Considerations May Influence US FDA's Efficacy Evaluation

 
• By Sarah Karlin-Smith
  
3d illustration of a T cell attacking a cancer cell
US FDA discusses efficacy and access trade-offs for CAR-T therapies. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards